Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Nasdaq Inc (NDAQ) Price & Performance

GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.

The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.

Nasdaq (NDAQ) trades at $93.48, down 0.86% on the day, with strong technical momentum showing a bullish moving average signal despite overbought RSI conditions. The company demonstrates robust fundamentals with 2025 revenue of $8.26B and net income of $1.79B, representing a 21.64% profit margin. Recent earnings beats and the launch of AI-powered Calypso platform highlight operational strength. Analyst consensus remains strongly bullish with a $110.43 price target, representing 18% upside potential from current levels.

NDAQ presents a compelling investment case with consistent earnings outperformance, strong profitability metrics, and strategic AI integration driving growth. However, elevated valuation multiples (P/E 27.25) and potential market volatility from exchange operations pose risks. The stock's technical positioning near resistance at $95 requires monitoring, but institutional support and positive analyst sentiment suggest continued upside potential for long-term investors.